Notch signaling activation contributes to cardioprotection provided by ischemic preconditioning and postconditioning
© Zhou et al.; licensee BioMed Central Ltd. 2013
Received: 19 August 2013
Accepted: 30 September 2013
Published: 8 October 2013
Notch signaling is known to be activated following myocardial ischemia, but its role in cardioprotection provided by ischemic preconditioning (IPC) and ischemic postconditioning (IPost) remains unclear.
Lentiviral vectors were constructed to overexpress or knockdown N1ICD in H9c2 cardiomyocyte and rat heart exposed to ischemia reperfusion injury (IRI), IPC or IPost.
Notch1 signaling was activated during myocardial IPC and IPost, and could enhance cell viability and inhibit apoptosis. Furthermore, activated Notch1 signaling stabilized mitochondrial membrane potential and reduced reactive oxygen species induced by IRI. The cardioprotection provided by activated Notch1 signaling resembled that of IPC and IPost, which was related to Stat3 activation and regulation of apoptosis related proteins. Furthermore, in langendorff heart perfusion model, activated Notch1 signaling restored cardiac function, decreased lactate dehydrogenase release and limited infarct size after myocardial ischemia. Conclusions: Notch1 signaling is activated and mediates cardioprotection provided by IPC and Ipost. Notch1 signaling may represent a potential new pharmacologic mimic for cardioprotection of ischemic heart disease.
KeywordsNotch signaling Mitochondrial permeability transition pore Stat3, Ischemic preconditioning Ischemic postconditioning
It is well known that immediate restoration of cardiac blood flow after prolonged ischemia would contradictorily result in ischemia reperfusion injury (IRI), which would accelerate the deterioration of cardiac function . Ischemia preconditioning (IPC) has shown beneficial effects such as limiting infarct size and reducing lethal arrhythmia after IRI in many species including human being [2, 3]. On the other hand, ischemia postconditioning (IPost) indicates brief episodes of nonlethal ischemia/reperfusion applied at the onset of reperfusion . Accumulating evidence indicates that IPC and IPost activate various survival signaling pathways to provide cardioprotection [5, 6]. Therefore, developing pharmacologic mimics such as endogenous autacoids to provide myocardial protection have important clinical significance for the treatment of ischemic heart disease (IHD).
Notch signaling is an evolutionary conserved signaling pathway which plays a crucial role in cell fate decision, cell differentiation, proliferation, and apoptosis . There are four receptors (Notch1-4) and five ligands (Jagged1-2 and Delta like 1, -3,-4) in mammals, the hairy and enhancer of split (Hes) and hes-related (Hey) families of transcriptional repressors have been identified as Notch classical target genes . Notch signaling has been implicated in heart disease. Notch1 and Jagged1 levels were lower in adult heart, but N1ICD, Jagged1 and Delta4 were accumulated in the border zone of the infarct region at 4 days after ischemia . Quantitative RT-PCR analysis revealed that the expression of Notch1-4, Jagged1 and Hes1 were increased within the first week following myocardial infarct . Notch signaling was activated in cardiomyocytes during post-infarction remodeling, and the expression of Notch1, Jagged1 and Hes1 were upregulated in dilated or hypertrophic hearts . In addition, Notch signaling can stimulate immature cardiomyocyte proliferation and promote quiescent cardiomyocytes to reenter the cell cycle [12, 13]. However, whether activated Notch signaling following myocardial ischemia plays cardioprotective effects during IPC and IPost remains unclear.
Therefore, in this study we investigated the role of Notch1 signaling in cardioprotection provided by IPC and IPost, using both cardiomyocyte and rat heart model. Our results showed that the inhibition of Notch1 signaling via the knockdown of N1ICD abrogated the cardioprotection provided by IPC and IPost.
Materials and methods
Reagents and antibodies
Dulbecco’s modified Eagle’s medium (DMEM) and trypsin were from Gibco BRL (USA). Fetal bovine serum (FBS) was from NQBB International Biological Corporation (Australia). Cell counting kit-8 (CCK-8) and Reactive oxygen species assay kits were from Beyotime institute of biotechnology (China). Annexin V-FITC apoptosis detection kit was obtained from KeyGEN Biotech(China). Mitochondria staining kit (JC-1) was purchased from MultiSciences Biotech (USA). Mitochondria isolation kit was purchased from Applygen Technologies (China). LDH kits were purchased from Nanjing jiancheng bioengineering institute, 2,3,5-triphenyltetrazolium chloride (TTC) was from SolarbioTechnologies (China). Enhanced chemiluminescence kit was purchased from Thermo Scientific (USA).
Notch1 and Hes1 antibodies were purchased from Abcam (USA), Flag, Bcl-xL and Bax antibodies were purchased from Cell Signaling Technology (USA), Stat3, p-Stat3 and β-Actin antibodies were purchased from Anbo Biotechnology Company (USA).
Rat cardiac H9c2 cells (ATCC Rockville, USA) were cultured in DMEM supplemented with 10% FBS at 37°C in a humidified incubator with 5% CO2. The cells were fed every 3 days and subcultured once reaching 90% confluence. Cells were plated at an appropriate density according to each experimental design.
Virus vector construction and infection
Rat N1ICD cDNA (Notch1:5456–7819) was generated by PCR using forward primer: 5′-GAGGATCCCCGGGTACCGGTCGCCACCATGGTGCTGCTGTCCCGCAAG-3′ and reverse primer: 5′-TCATCCTTGTAGTCGCTAGCCTTAAATGCCTCTGGAATG-3′. The amplified fragment was subcloned into pGC-FU-EGFP-3Flag to get pGC-FU-N1ICD-3Flag vector. Rat N1ICD-shRNAs were designed according to Ambion with the following sequences: GCACAGTGCTGAGTACCAA (N1ICD-shRNA-1), GCCTCTCCACCAATACCTT (N1ICD-shRNA-2), CCCACATTCCAGAGGCATT (N1ICD-shRNA-3), TCTGGATGCCCGAATGCAT (N1ICD-shRNA-4) with CTCGAG as the loop sequence. The oligonucleotide-annealed products were subcloned into pGVC112 to get pGVC112-N1ICD-shRNA vectors. An irrelevant TTCTCCGAACGTGTCACGT was used as negative control.
To generate lentiviral vectors, either 20 μg pGC-FU-N1ICD-3Flag or pGVC112-N1ICD-shRNA was transfected along with 15 μg pHelper 1.0 and 10 μg pHelper 2.0 into 293T cells in 10 cm plate at 80% confluence for 8 h. The medium was replaced with fully supplemented DMEM and the supernatants were harvested after 72 h for virus titration, which were then stored at −80°C.
To infect H9c2 cells, multiplicity infection (MOI) of 20 lentiviral particles with 5 μg/ml polybrene were added into the medium, 24 h later the medium was changed and H9c2 cells were cultured for an additional 72 h.
To infect Sprague–Dawley rat, 100 μl pseudo viral particles (1×108/ml) were injected into the tail vein, 4 weeks after infection, Sprague–Dawley rats were collected for analysis.
In vitro protocols of hypoxia/reoxygenation (H/R), IPC, IPost
For H/R, H9c2 cells were cultured in hypoxic solution in a hypoxic incubator (95% N2-5% CO2) for 3 h, subsequently hypoxic solution was replaced with reoxygenation solution, and the cells were cultured in a high oxygen incubator (95% O2-5% CO2) for 3 h.
For IPC, H9c2 cells were cultured in hypoxic solution in a hypoxic incubator (95% N2-5% CO2) for 10 min, subsequently the hypoxic solution was replaced with reoxygenation solution, and the cells were cultured in a high oxygen incubator (95% O2-5% CO2) for 10 min. The hypoxia-reoxygenation cycle was repeated 3 times and followed by H/R treatment.
For IPost, at the end of the 3 h hypoxia, the hypoxic solution was replaced with reoxygenation solution and H9c2 cells were cultured in a high oxygen incubator for 10 min. Next the medium was changed to hypoxic solution and the cells were cultured in a hypoxic incubator for another 10 min. The reoxygenation-hypoxia cycle was repeated 3 times and followed by continuous culture in reoxygenation solution in a high oxygen incubator for 3 h.
Cell viability assay
H9c2 cells were seeded into a 96-well plate at 10,000 cells/well and cultured in 100 μL DMEM supplemented with 10% FBS for 24 h, then treated as indicated. Finally, the cell viability was detected using CCK-8 Kit (Dojindo, Japan) according to the manufacturer’s instructions. The absorbance was measured at 450 nm using a Microplate reader (Thermo, USA). The percentage of viable cells was calculated with the control cells set as 100%.
H9c2 cells were harvested and 4×105 cells were resuspended in 500 μl binding buffer, then incubated with 5 μl Annexin V-FITC and 5 μl propidium iodide (PI) at room temperature in dark for 15 min. The samples were analyzed by flow cytometry with a BD FACSCalibur. Apoptosis ratio was defined as the ratio between Annexin V positive/PI negative cells and the total living cells.
Detection of intracellular reactive oxygen species (ROS)
H9c2 cells were harvested and 105 cells were incubated with 10 μmol/L DCFH-DA at 37°C for 20 min. The DCF fluorescence was detected by BD FACSCalibur excited at 488 nm and the emitted fluorescence was collected at 525 nm.
Determination of mitochondrial membrane potential (ΔΨm)
H9c2 cells were harvested and 105 cells were loaded with JC-1 (2 μM) at 37°C, 5% CO2 for 20 min, then analyzed by BD FACSCalibur excited at 488 nm and the emitted fluorescence was collected at 530 nm and 590 nm. ΔΨm was expressed as the emitted fluorescence ratio (590/530 nm) in percentage to the initial level, whereas 0% level was recorded after complete mitochondrial depolarization with carbonyl cyanide-p-trifluoromethoxyphenylhydra-zone.
Langendorff heart perfusion
Male Sprague–Dawley rats (weight 220 to 250 g) were obtained from Jiangxi University of Traditional Chinese Medicine (China). All animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals, and approved by the Ethics Committee of the first affiliated hospital of Nanchang University (permit No: NDYFY-2012-YYLSD-016). The rats were anesthetized with pentobarbital sodium (100 mg/kg intraperitoneally). Hearts were excised and retrograde perfused via the aorta with modified Krebs-Henseleit buffer (NaCl 118 nM, KCl 4.7 nM, MgSO4 1.2 nM, CaCl2 2.5 nM, NaHCO3 2 nM, KH2PO4 1.2 nM, Glucose 11 nM, pH 7.35-7.45) equilibrated with 95% O2-5% CO2. Left ventriculardeveloped pressure (LVDP), heart rate (HR) and intraventricular pressure (±dP/dt) were measured by Powerlab pressure transducer with a balloon inserted into the left ventricle. In the Control, Mock1 and Mock2 groups, hearts were buffer perfused without ischemia. In ischemia/reperfusion (I/R) group, hearts were first equilibrated for 20 min followed by 30 min of stop-flow ischemia and 120 min of reperfusion. In IPC group, after 3 cycles of 5 min of ischemia and 5 min of reperfusion, hearts were subjected to 30 min of no-flow ischemia, followed by 120 min of reperfusion. In IPost group, hearts were subjected to 30 min of stop-flow ischemia, before 120 min of reperfusion, 3 cycles of 10 s of ischemia and 10 s of reperfusion were applied.
Lactate dehydrogenase (LDH) assay
Coronary effluent was collected at 1 min before ischemia, 1 min after ischemia and 1 min after reperfusion to determine LDH activity by using LDH kits according to the manufacturer’s instructions. LDH activity was expressed as international units per liter (IU/L).
Assessment of infarct size
The heart was frozen at −20°C for 30 min, then sectioned from apex to base into five to six 1 mm sections. The sections were incubated in 1%TTC at 37°C for 30 min and fixed in 10% formaldehyde for 24 h. The normal myocardium was stained brick red with TTC while the infarcted portion was not stained and appeared pale white. The infarct area-IA (white) and the area at risk-AAR (red and white) from each section were measured using Image Pro 6.0 Plus software. For each section, infarct size was expressed as the percentage of IA/AAR.
Western blot analysis
At different time points of the experiemtns, cells or the hearts were harvested immediately and lysed in cell lysis buffer (Beyotime Institute of Biotechnology, China) at 4°C. Protein samples were separated by 8-10% SDS-PAGE, then transferred to nitrocellulose membranes (Millipore) and blocked in 10% nonfat milk in TBST (150 mM NaCl, 50 mM Tris pH 7.5, 0.1% Tween-20). Membranes were incubated with primary antibodies overnight at 4°C, followed by incubation with secondary antibodies at room temperature for 1 h. The fluorescent signals were detected using enhanced chemiluminescence by ImageQuant LAS4000 (GE, USA). Relative protein levels were normalized to that of β-actin.
Data were analyzed using the SPSS version 12 statistical analysis package (SPSS Inc., Chicago, IL, USA). Examined data were assessed using ANOVA. In each test, the data were expressed as the mean±SD, and P<0.05 was accepted as statistically significant.
Identification of LV-N1ICD and LV-N1ICD-shRNA vectors
Notch1 signaling is activated during myocardial IPC and IPost
Myocardial IRI is mitigated by activated Notch1 signaling
Next, we observed the effect of Notch1 signaling on cell apoptosis after myocardial ischemia. The results demonstrated that the apoptosis of cardiomyocyte in H/R was greatly reduced after N1ICD overexpression, but it was substantially increased upon N1ICD knockdown during IPC and IPost (Figure 3B). Taken together, these data suggest that Notch1 signaling mitigates myocardial IRI by promoting the viability and inhibiting the apoptosis of cardiomyocytes.
Notch1 signaling inhibits the mitochondrial permeability transition pore (mPTP) opening in cardiomyocytes
Next we measured intracellular ROS in H9c2 cells and found that ectopic expression of N1ICD mitigated ROS accumulation caused by H/R, but knockdown of N1ICD promoted ROS accumulation during IPC and IPost (Figure 4B). These data suggest that Notch1 signaling inhibits mPTP opening in cardiomyocytes via the reduction of intracellular ROS accumulation.
Notch1 signaling activates Stat3 and regulates apoptosis related proteins in cardiomyocytes
Furthermore, we detected anti-apoptosis protein Bcl-xl and pro-apoptosis protein Bax in H9c2 cells. The results showed that ectopic expression of N1ICD increased Bcl-xl expression and decreased Bax expression under H/R, but N1ICD knockdown during IPC or IPost decreased Bcl-xl level and increased Bax level (Figure 5B). Collectively, these data provide evidence that cardioprotection effects of Notch1 signaling are mediated by Stat3 activation and regulation of apoptosis related proteins.
Notch1 signaling contributes to the restoration of cardiac function in post-ischemia rats
Notch1 signaling reduces myocardial necrosis after ischemia in rats
The activation of Notch signaling following tissue injury has been documented in various tissues [14, 15]. In this study we observed that the expression of N1ICD and Hes1 was greatly increased in H9c2 cells exposed to IPC and IPost, but not to H/R, suggesting that endogenous cardioprotection phenomenon is associated with the activation of Notch signaling. These data are consistent with recent findings that Notch1 signaling is implicated in myocardial protection mediated by IPC . In addition, we found that IR-induced necrosis and apoptosis in H9c2 cardiomyocytes were mitigated by activated Notch1 signaling. Furthermore, in langendorff isolated heart perfusion model, we demonstrated that activation of Notch1 not only reduced the release of LDH and limited the infarct size, but also improved cardiac function after ischemia. Collectively, these data suggest that Notch1 acts as an endogenous cardioprotcetive factor to play an important role in the protection of ischemic myocardium during IPC and IPost.
mPTP is a non-specific channel in the mitochondrial inner membrane. Experimental evidences suggest that irreversible opening of mPTP is a critical mediator of lethal IRI, but IPC and IPost can direct or indirectly inhibit the opening of mPTP by various survival signaling pathway . In the present study, we monitored the mPTP opening by ΔΨm and found that activated Notch1 alleviated the loss of ΔΨm induced by H/R, while knockdown of N1ICD during IPC and IPost exacerbated the loss of ΔΨm. These results indicate that the mPTP opening induced by H/R is partly inhibited by Notch1 signaling. Furthermore, we found that Notch1 decreased the production of intracellular ROS during H/R, in agreement with previous results that Notch1 signaling protected hepatocytes from IRI by repressing ROS .
Cardiomyocyte apoptosis is a complex molecular event controlled by a variety of apoptosis related proteins such as Bcl-2 family. The Bcl-2 family consists of pro-apoptotic factors such as Bad, Bid and Bax, and anti-apoptotic factors such as Bcl-2 and Bcl-xl. Bax can directly induce mPTP opening, leading to the release of cytochrome C and the activation of apoptotic signaling pathways . Notch signaling could upregulate Bcl-2 and Bcl-xl expression and downregulate Bax and Bim expression, thereby inhibiting apoptosis . In current study, the upregulation of Bax and downregulation of Bcl-xl induced by H/R were reversed by activated Notch1 signaling, but were promoted upon knockdown of N1ICD during IPC and IPost. Therefore, we propose that Notch1 inhibits myocardial apoptosis induced by IRI through regulating the expression of Bcl-2 family members.
Several studies have shown that the activation of Stat3 in IR not only reduces cardiomyocyte death, but also attenuates adverse cardiac remodeling [21, 22]. Furthermore, myocardial IPC and IPost can enhance Stat3 phosphorylation and activity, which contribute to the cardioprotection provided by IPC and IPost [23, 24]. In the current study, Stat3 phosphorylation was upregulated during endogenous cardioprotection mediated by IPC and IPost, but was inhibited upon the knockdown of N1ICD. These data suggest that Notch1 signaling prevents myocardium from IRI by enhancing Stat3 phosphorylation and activation.
In summary, in this study we provide a series of evidence that Notch1 signaling is activated and mediates cardioprotection provided by IPC and IPost. Notch1 signaling exerts endogenous cardioprotection to mitigate IRI through the inhibition of mPTP opening, the regulation of Bcl-2 family member expression, and the activation of Stat3. Our results suggest that Notch1 signaling may represent a potential new pharmacologic mimic for cardioprotection of IHD.
This work was supported in part by grants from the National Natural Science Foundation of China (No: 81260024), the Natural Science Foundation of Jiangxi Province (No: 20122BAB205026, No: 20132BAB205033).
- Minamino T: Cardioprotection from ischemia/reperfusion injury: basic and translational research. Circ J. 2012, 76: 1074-1082. 10.1253/circj.CJ-12-0132.View ArticlePubMedGoogle Scholar
- Gerczuk PZ, Kloner RA: An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol. 2012, 59: 969-978. 10.1016/j.jacc.2011.07.054.View ArticlePubMedGoogle Scholar
- Apostolakis E, Baikoussis NG, Papakonstantinou NA: The role of myocardial ischaemic preconditioning during beating heart surgery: biological aspect and clinical outcome. Interact Cardiovasc Thorac Surg. 2012, 14: 68-71. 10.1093/icvts/ivr024.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J: Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003, 285: H579-588.View ArticlePubMedGoogle Scholar
- Huang C, Yitzhaki S, Perry CN, Liu W, Giricz Z, Mentzer RM, Gottlieb RA: Autophagy induced by ischemic preconditioning is essential for cardioprotection. J Cardiovasc Transl Res. 2010, 3: 365-373. 10.1007/s12265-010-9189-3.PubMed CentralView ArticlePubMedGoogle Scholar
- Babiker FA, van Golde J, Vanagt WY, Prinzen FW: Pacing postconditioning: impact of pacing algorithm, gender, and diabetes on its myocardial protective effects. J Cardiovasc Transl Res. 2012, 5: 727-734. 10.1007/s12265-012-9390-7.View ArticlePubMedGoogle Scholar
- Schwanbeck R, Martini S, Bernoth K, Just U: The notch signaling pathway: molecular basis of cell context dependency. Eur J Cell Biol. 2011, 90: 572-581. 10.1016/j.ejcb.2010.10.004.View ArticlePubMedGoogle Scholar
- Kopan R: Notch signaling. Cold Spring Harb Perspect Biol. 2012, 4: 10-doi:10.1101/cshperspect.a011213View ArticleGoogle Scholar
- Gude NA, Emmanuel G, Wu W, Cottage CT, Fischer K, Quijada P, Muraski JA, Alvarez R, Rubio M, Schaefer E, Sussman MA: Activation of notch-mediated protective signaling in the myocardium. Circ Res. 2008, 102: 1025-1035. 10.1161/CIRCRESAHA.107.164749.PubMed CentralView ArticlePubMedGoogle Scholar
- Kratsios P, Catela C, Salimova E, Huth M, Berno V, Rosenthal N, Mourkioti F: Distinct roles for cell-autonomous notch signaling in cardiomyocytes of the embryonic and adult heart. Circ Res. 2010, 106: 559-572. 10.1161/CIRCRESAHA.109.203034.View ArticlePubMedGoogle Scholar
- Croquelois A, Domenighetti AA, Nemir M, Lepore M, Rosenblatt-Velin N, Radtke F, Pedrazzini T: Control of the adaptive response of the heart to stress via the notch1 receptor pathway. J Exp Med. 2008, 205: 3173-3185. 10.1084/jem.20081427.PubMed CentralView ArticlePubMedGoogle Scholar
- Collesi C, Zentilin L, Sinagra G, Giacca M: Notch1 signaling stimulates proliferation of immature cardiomyocytes. J Cell Biol. 2008, 183: 117-128. 10.1083/jcb.200806091.PubMed CentralView ArticlePubMedGoogle Scholar
- Campa VM, Gutierrez-Lanza R, Cerignoli F, Diaz-Trelles R, Nelson B, Tsuji T, Barcova M, Jiang W, Mercola M: Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. J Cell Biol. 2008, 183: 129-141. 10.1083/jcb.200806104.PubMed CentralView ArticlePubMedGoogle Scholar
- Lovschall H, Tummers M, Thesleff I, Fuchtbauer EM, Poulsen K: Activation of the notch signaling pathway in response to pulp capping of rat molars. Eur J Oral Sci. 2005, 113: 312-317. 10.1111/j.1600-0722.2005.00221.x.View ArticlePubMedGoogle Scholar
- Givogri MI, de Planell M, Galbiati F, Superchi D, Gritti A, Vescovi A, de Vellis J, Bongarzone ER: Notch signaling in astrocytes and neuroblasts of the adult subventricular zone in health and after cortical injury. Dev Neurosci. 2006, 28: 81-91. 10.1159/000090755.View ArticlePubMedGoogle Scholar
- Yang Y, Duan W, Jin Z, Bi S, Yan J, Jin Y, Lu J, Yang J, Yi D: New role of notch-mediated signaling pathway in myocardial ischemic preconditioning. Med Hypotheses. 2011, 76: 427-428. 10.1016/j.mehy.2010.11.011.View ArticlePubMedGoogle Scholar
- Hausenloy DJ, Ong SB, Yellon DM: The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol. 2009, 104: 189-202. 10.1007/s00395-009-0010-x.View ArticlePubMedGoogle Scholar
- Yu HC, Qin HY, He F, Wang L, Fu W, Liu D, Guo FC, Liang L, Dou KF, Han H: Canonical notch pathway protects hepatocytes from ischemia/reperfusion injury in mice by repressing reactive oxygen species production through jak2/stat3 signaling. Hepatology. 2011, 54: 979-98826. 10.1002/hep.24469.View ArticlePubMedGoogle Scholar
- Kinnally KW, Antonsson B: A tale of two mitochondrial channels, mac and ptp, in apoptosis. Apoptosis. 2007, 12: 857-868. 10.1007/s10495-007-0722-z.View ArticlePubMedGoogle Scholar
- Gao F, Yao M, Shi Y, Hao J, Ren Y, Liu Q, Wang X, Duan H: Notch pathway is involved in high glucose-induced apoptosis in podocytes via bcl-2 and p53 pathways. J Cell Biochem. 2013, 114: 1029-1038. 10.1002/jcb.24442.View ArticlePubMedGoogle Scholar
- Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, Schulz R: Cardioprotection by ischemic postconditioning is lost in aged and stat3-deficient mice. Circ Res. 2008, 102: 131-135. 10.1161/CIRCRESAHA.107.164699.View ArticlePubMedGoogle Scholar
- Obana M, Maeda M, Takeda K, Hayama A, Mohri T, Yamashita T, Nakaoka Y, Komuro I, Matsumiya G, Azuma J, Fujio Y: Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation. 2010, 121: 684-691. 10.1161/CIRCULATIONAHA.109.893677.View ArticlePubMedGoogle Scholar
- You L, Li L, Xu Q, Ren J, Zhang F: Postconditioning reduces infarct size and cardiac myocyte apoptosis via the opioid receptor and jak-stat signaling pathway. Mol Biol Rep. 2011, 38: 437-443. 10.1007/s11033-010-0126-y.View ArticlePubMedGoogle Scholar
- Hausenloy DJ, Lecour S, Yellon DM: Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: Two sides of the same coin. Antioxid Redox Signal. 2011, 14: 893-907. 10.1089/ars.2010.3360.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.